Emerging molecular target antagonists for the treatment of biliary tract cancer

Original Citation: Emerging molecular target antagonists for the treatment of biliary tract cancer / Lombardi, Pasquale; Marino, Donatella*; Fenocchio, Elisabetta; Chilà, Giovanna; Aglietta, Massimo; Leone, Francesco. - In: EXPERT OPINION ON EMERGING DRUGS. - ISSN 1472-8214. - 23:1(2018), pp. 63-75.

Availability: This version is available http://hdl.handle.net/2318/1663851 since 2018-03-26T16:28:30Z

Published version: DOI:10.1080/14728214.2018.1444749

Terms of use: Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Emerging molecular target antagonists for the treatment of biliary tract cancer

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Expert Opinion On Emerging Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>EOMD-2017-0036.R1</td>
</tr>
<tr>
<td>Manuscript Type</td>
<td>Review</td>
</tr>
<tr>
<td>Keywords:</td>
<td>biliary tract cancer, cholangiocarcinoma, emerging drugs, immunotherapy, growth factor receptor, molecular targeted drugs, FGFR, IDH1</td>
</tr>
</tbody>
</table>
Title
Emerging molecular target antagonists for the treatment of biliary tract cancer

Abstract
Introduction: Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is cisplatin/gemcitabine combination, whereas no standard in 2nd-line has been defined. Hence, the current goal is to better understand the biology of BTCs, discovering new treatment methods and improving clinical outcomes.

Areas covered: The development of next-generation-sequencing has unveiled the picture of the molecular signatures characterizing BTCs, leading to the identification of actionable mutations in biomarker-driven clinical trials. In this review we will cover the genetic landscape of BTC, focusing on the efficacy of existing treatments. Furthermore, we will discuss emerging molecular targets and evaluate the findings of pre-clinical studies. Finally, the encouraging results of clinical trials involving targeted therapies or immunotherapy will be reviewed.

Expert opinion: FGFR fusion rearrangements and IDH1 or IDH2 mutations are the most promising targeted treatments under evaluation. In addition, innovative trial design will allow to offer a chance for tailored medicine to infrequent subgroups of BTCs patients based on their molecular features rather than their histology.

Manuscript

1-Background
Biliary tract cancer (BTC) is a heterogeneous group of tumors arising from the epithelial lining of the biliary tree. The classification is based according to the anatomical location; BTC includes gallbladder cancer (GBC) and cholangiocarcinoma (CCA); the latter is further divided into intrahepatic (IH-CCA), and extrahepatic (EH-CCA), which includes EH-CCA perihilar (PCCA) and distal CCA (DCCA). IH-CCAs arise above the second order bile ducts, whereas PCCAs are located between the insertion of the cystic duct and the second order bile ducts, and DCCAs are located below the insertion of the cystic duct [1, 2].
Even though GBC, intrahepatic, perihilar and distal extrahepatic CCA are grouped as BTCs, their clinical presentation, pathobiology and management are different, and they should be viewed as separate entities. Despite being considered an infrequent cancer in the Western world, with an incidence of 1-2 cases every 100,000 inhabitants, BTCs are extremely common in South America and in some areas of Asia, with up to 96 cases/100,000 [3].

Histologically, more than 95% of BTCs are adenocarcinomas, often poorly differentiated. About 10% of EH-CCA are well differentiated papillary cancers, but mucinous (5%) and squamous cancers (2%) are also described [4]. Several classifications have been proposed for IH-CCA owing to its highly heterogeneity. The two main histological subtypes are bile ductular type (mixed), arising from small intrahepatic bile ducts, and bile duct type (mucinous), arising from large intrahepatic bile ducts. These differences are also reflected in different molecular characteristics [5]. Notably, bile ductular type IH-CCAs share clinicopathological similarities with cytokeratin (CK) 19-positive hepatocellular carcinoma (HCC), and the bile duct type IH-CCAs share phenotypic traits with PCCA and pancreatic cancers [6].

Beyond the differences, BTC have common features, such as a highly desmoplastic reaction, rich tumor microenvironment, and profound genetic heterogeneity, all contributing to the development of drug resistance and almost complete absence of curative therapies for metastatic disease.

The vast majority of BTC (70%) occurs sporadically. Nevertheless, several pathologic conditions have been determined as possible risk factors such as Primary Sclerosing Cholangitis (PSC), choledochal cysts, parasitic infestation, and viral hepatitis B and C. Potential risk factors with less evidence are diabetes, alcohol, smoking, obesity and specific genetic polymorphisms [7]. Therefore, although a single trigger cannot be identified, different environmental, genetic and social factors may be rather involved and justify heterogeneous geographic distribution.

Most patients with early stage disease are asymptomatic and diagnosing BTC at an early stage remains a challenge owing to its ‘silent’ clinical presentation, difficult to access anatomical location, and highly desmoplastic, paucicellular nature, which limits the sensitivity of cytological and pathological diagnostic approaches.

Surgery is the preferred treatment option for localized BTC, but only a minority of patients (approximately 35%) has early stage disease that is amenable to surgical resection with a curative intent. Survival after radical surgery generally depends on margin status (negative-R0 or positive-R1-R2 status), vascular invasion and lymph node involvement. Even after R0 resection 3-years survival rate is approximately 40-60%, and it can be lower in
case of lymph node positivity [8].

The unfavorable prognosis of recurrent disease drove efforts to lower the rate of relapse through postoperative adjuvant therapy. So far, the great part of the available literature was made of retrospective, non-randomized studies and meta-analyses: the majority took in consideration heterogeneous populations of patients, treated with different systemic drugs with or without radiotherapy. Recently, following the presentation of the preliminary results of the BILCAP study, a standard of care for adjuvant treatment is available. In this randomized phase III trial, postoperative capecitabine was compared to surveillance: the primary endpoint of the study was formally not met, despite a difference of 15 months in the median overall survival (mOS) estimated values (51 versus 36 months, \( p = 0.097 \)). However, mOS was significantly higher in the chemotherapy arm both after sensitivity analyses and in the per protocol analysis [9].

For patients with advanced-stage or unresectable disease, the available systemic therapies are of limited effectiveness: the mOS with the current standard-of-care regimen (gemcitabine and cisplatin) is <1 year [10] and a probability to outlive 5 years is about 5% [11].

2-Medical need

Randomized trials have shown that systemic chemotherapy increases survival and improves quality of life (QoL) in patients with metastatic BTC as compared with best supportive care (BSC). In the study by Glimelius, 90 patients with metastatic or locally advanced pancreatic carcinoma or BTC have been randomly assigned to 5-fluorouracil (5-FU) -based chemotherapy or BSC. A clear benefit of chemotherapy on both mOS (6 vs 2.5 months in BSC group \( p< 0.01 \)) and QoL was demonstrated [12]. More recently, modified gemcitabine and oxaliplatin (mGEMOX) proved a significant improvement in mOS not only over BSC, but also over 5-FU/folinic acid in unresectable GBC (9.5, 4.6 and 4.5 months respectively)[13].

The majority of trials in the metastatic setting were performed with fluoropyrimidine or gemcitabine monotherapy or in combination with other cytotoxic agents. 5-FU as single agent yields a variable response rates (RR) from 10% to 40%. The combination of 5FU with other drugs (etoposide, interferon, cisplatin and oxaliplatin) has proved moderate efficacy, limited overall survival (OS) benefit, and a significantly greater toxicity profile. Since the late 90s, the adoption of gemcitabine as the standard of care for patients with pancreatic cancer led to interest in its use for hepatobiliary tumors. As a single agent, gemcitabine has shown RRs ranging from 0% to 30%, whereas its association with other agents has determined advantages in survival and RRs (up to 41%) [14]. In 2007 a pooled analysis of 104 trials in advanced BTC, demonstrated the superiority
of combination therapy compared to monotherapy in RR and tumor-control-rate (TCR). Subgroup analysis also underlined that gemcitabine and platinum association had significantly higher response and TCRs compared to fluoropyrimidine/gemcitabine monotherapy or fluoropyrimidine plus platinum regimens [15].

Suggestions from this meta-analysis were turned into a standard of care by Valle’s Phase III ABC-02 trial. Four hundred and ten patients with locally advanced or metastatic CCA, GBC and ampullary carcinoma were randomly assigned to receive gemcitabine alone (1000 mg/m² days 1, 8, 15 q 28) vs gemcitabine and cisplatin (1000 mg/m² + 25 mg/m² days 1, 8 q 21) for up to 24 weeks of treatment. After a median follow-up of 8.2 months, mOS, that was the primary endpoint of the study, was statistically improved in the combination arm (11.7 vs. 8.1 months; \( p < 0.001 \)). The benefit was preserved across the subgroups according to primary tumor site, median progression-free-survival (mPFS) was improved (8.0 months vs. 5.0 months; \( p < 0.001 \)), without significant increase in toxicity. [10]. Following the results of this trial, a definite standard regimen for a disease that has been “orphaned” for too long, was finally provided. Equivalent results have been replicated in the Japanese population [16]. Other combination schemes have also been evaluated as first line treatment in phase II trials [17-19]. Among these, gemcitabine and oxaliplatin (GEMOX) is widely used in clinical practice for its good response rate and favorable toxicity profile, although a direct comparison with the standard of care is lacking [13, 20].

Following a meta-analysis of the English and Japanese randomized trials, single agent gemcitabine is a recommended option only for patients with Performance Status (PS) 2 according to Eastern Cooperative Oncology Group (ECOG) scale [21].

After the failure of the 1st line therapy, approximately half of the patients still have a good PS and satisfactory organ function [22], but the advantages of 2nd line therapy are still unclear. In a large retrospective analysis, 196 patients who received 2nd line treatment after gemcitabine and cisplatin/oxaliplatin, were analyzed. The most common regimens used were 5-FU/folinic acid, FOLFIRI, XELIRI, FOLFOX, XELOX, 5-FU and cisplatin: globally, the outcome was poor, the mPFS and OS being 3.2 and 6.7 months, respectively, and no chemotherapy regimen proved superiority over the others [23]. In another Italian retrospective analysis, PS emerged as the most important prognostic factor to select the patients that may benefit from 2nd line treatment [24].

3-Existing treatment

In the past decade we have entered the era of targeted therapies: this strategy has modified the therapeutic approach of many cancers but the first attempts of using targeted treatments in BTCs have been so far unsatisfactory. Here, we revise the first studies that have explored targeted therapies in BTC.
3.1 EGFR family pathway

Epidermal growth factor receptor (EGFR) is mutated and overexpressed in cancer human samples. EGFR is extensively represented in BTC, being expressed in 100% of IH-CCAs, 52.6% of EH-CCAs, and 38.5% of GBCs [25]. Mutations have been found in up to 15% of BTCs [26, 27]. EGFR activation triggers the Mitogen Activated Proteine Kinases (MAPK)–ERK pathway, an oncogenic signalling pathway in cancer: it donates a proliferative advantage to cancer cell, contributes to progression through epithelian-mesenchymal transition (EMT) and leads to a poor clinical outcome [28, 29]. In preclinical studies, EGFR inhibitors tested in combination with chemotherapy have shown promising activity, providing a strong preclinical rationale for anti-EGFR therapy in BTC. Different strategies targeting EGFR have been studied such as tyrosine kinase inhibitors (TKIs) or monoclonal antibodies (mAbs) alone or in association with chemotherapy.

Erlotinib, a selective, reversible, orally-active EGFR inhibitor, after promising results in several phase II studies, failed to confirm its superiority in OS in a large phase III study. Compared to the combination of GEMOX, the addition of erlotinib in patients with newly diagnosed metastatic BTC significantly increased RR (40% vs 21%; $p=0.005$) but mPFS and OS were not increased (4.2 vs 5.8 months $p=0.087$ and 9.5 months in both arms, $p=0.611$ respectively). Subgroup analyses showed that in patients with CCA the addition of erlotinib prolonged mPFS (5.9 months vs 3.0 months; HR 0.73, 95% CI 0.53–1.00; $p=0.049$) [30].

Cetuximab is a mAb targeting EGFR, evaluated in combination with chemotherapy in BTC in several phase II trials. In a phase II study of cetuximab in combination with GEMOX, the treatment achieved a mPFS of 8.3 months and OS of 12.7 months, with high RR [31]. Following randomized trials failed to demonstrate a significant benefit of the GEMOX and cetuximab combination. In the BINGO study, cetuximab was tested in the 1st line setting in addition to GEMOX vs GEMOX alone. Despite being well tolerated, cetuximab did not significantly improve outcomes: mPFS was 6.1 months with cetuximab and 5.5 months without cetuximab, while mOS was 11.0 months with cetuximab and 12.4 months without cetuximab [32]. In a similar study in the Asiatic population, mPFS was 6.7 months with cetuximab and 4.1 months without cetuximab ($p = 0.05$), while mOS was 10.6 months vs 9.8 months respectively ($p = 0.91$). KRAS mutations, that are a well-known negative predictive factor of response to anti-EGFR mAbs, were identified in 36% of tumors, and did not affect the overall response rate (ORR) or mPFS [33].

Panitumumab, a fully human antibody against EGFR, has been tested in combination with chemotherapy in non-randomized and randomized, phase II trials. In particular, in the Vecti-BIL trial advanced BTC patients were selected upfront for KRAS mutational status. The study revealed that the addition of panitumumab to GEMOX compared to GEMOX alone did not significantly improve mPFS, (5.3 months in experimental arm vs 4.4 months...
in control arm), neither OS (10.2 months in experimental arm vs 9.9 months in control arm) in KRAS wild type (WT) BTC patients [34].

Despite the results of a recent meta-analysis suggesting a potential role of anti-EGFR therapy in prolonging PFS and RR, the current evidence does not support its use in BTC [35].

3.2 MEK pathway

Targeting the RAS/RAF/MEK/ERK pathway, a major player in the cellular processes, including proliferation and apoptosis, is thought to be a winning strategy in many cancers including BTC.

The second-generation, uncompetitive inhibitor of MEK 1/2 - selumetinib - was investigated in a phase II study of 28 advanced BTC patients. Median PFS was 3.7 months and the mOS was 9.8 months, with a 12% of ORR [52]. Recently a Phase Ib trial has tested the pharmacokinetics and toxicity profile of selumetinib in combination to cisplatin and gemcitabine. Other trials are needed to demonstrate its applicability in clinical practice [53].

Another uncompetitive inhibitor of MEK 1/2, binimetinib, after encouraging results in safety and activity during phase I studies [54], is currently under evaluation in phase II studies (NCT02151084, NCT01828034).

Recently, the open-label, multicentre, single-arm trial, evaluating pazopanib - an orally available multikinase inhibitor of VEGF (vascular endothelial growth factor) receptor, PDGF (platelet-derived growth factor) receptor, c-KIT (stem-cell growth factor receptor), fibroblast growth factor receptor (FGFR) and RAF - in addition to trametinib - an orally available highly specific inhibitor of MEK 1 and MEK 2 - showed discouraging results. Despite the trend towards increased 4-month PFS, the difference did not reach statistical significance. The mOS was 6.4 months (95% CI: 4.3–10.2) and the ORR was 5% (95% CI: 0.13–24.9%) [55].

3.3 VEGF

The vascular endothelial growth factor (VEGF) pathway promotes tumor growth - by angiogenesis and vascular permeability - in several tumors including BTC [36]. In CCA, VEGF expression is reported in about 30-40% of cases and is correlated with lymphnode metastasis and poor prognosis [37, 38]. VEGF expression is reported in 50% of GBC and also in this sub-group a poor prognosis is observed [39]. Based on preclinical and clinical data supporting a VEGF-targeted approach, several studies have evaluated the effectiveness and applicability of targeted therapy (bevacizumab, sorafenib, cediranib, vandetanib) in metastatic BTC, providing only limited information, principally because of their phase II design. Therefore, the role of antiangiogenic agents in the treatment of BTC is not well defined.
Bevacizumab is a recombinant humanized mAb whose efficacy has been tested in patients affected by advanced BTC. In two studies it was tested in combination with erlotinib and in sequence with gemcitabine and oxaliplatin, without favorable results [40, 41]. More recently, a small phase II study evaluated the combination of gemcitabine, capecitabine, and bevacizumab in a first-line setting, showing a mPFS and mOS similar to those observed with standard chemotherapy (8.1 months and 11.3 months, respectively) [42]. Larsen et al. recently presented the results of a phase II trial of capecitabine, irinotecan, gemcitabine, and bevacizumab as second-line setting in 50 BTC patients. Median PFS was 3.6 months and mOS was 6.4 months [43]. To date, the role of bevacizumab on BTC has been evaluated only in single-arm studies, with no randomized study performed.

Cediranib is a potent inhibitor of the VEGF receptor tyrosine kinases -also directed against PDGF receptors and c-KIT being investigated in a recent phase II study [44]. Patients were randomized to receive cisplatin and gemcitabine plus either cediranib or placebo. Cediranib did not significantly improved mPFS (7.7 months in the cediranib arm vs. 7.4 months in the placebo arm). There was a trend towards longer OS in the experimental arm compared to placebo (14.1 vs 11.9 months, respectively) [45].

For definitive conclusions, we will have to wait for the results of the ongoing phase II trial, investigating cediranib in combination with modified FOLFOX6 in advanced BTC (NCT01229111).

Sorafenib is an oral multikinase inhibitor directed against VEGF receptors and PDGF receptor-β, and blocking downstream intracellular serine/threonine kinases, like Raf-1, WT and mutant B-Raf.

After the defeats in monotherapy in several studies, the more recent conducted by Luo et al [46], Sorafenib was evaluated in combination with standard chemotherapy.

First, Moehler et al. investigated Sorafenib in the first line setting, treating patients with gemcitabine with either sorafenib or placebo. In this study, longer mPFS and OS were found in the gemcitabine plus placebo arm [47]. Then, a randomized, double-blinded, multicenter phase II trial investigating a combination of gemcitabine, cisplatin with either sorafenib or placebo demonstrated no significant difference in mPFS and mOS between the two arms [48]. Finally, a small trial conducted by Lee et al. showed that the addition of sorafenib to gemcitabine and cisplatin did not improve efficacy over historical data, but there was an increase of toxicity [49].

Sunitinib is another oral small molecular-targeted drug inhibiting several intracellular and receptor protein kinases, including VEGF and PDGF receptors, c-KIT, and rearranged during transfection (RET). In the only available phase II study, the role of sunitinib was investigated as a second-line treatment in advanced BTC demonstrating only marginal efficacy; ORR was 8.9 % and mPFS was 1.7 months [50].
Vandetanib is an orally active, multikinase inhibitor targeting VEGF receptor 2, EGFR and RET kinase. In the Italian "VanGogh" study, 165 BTC patients chemotherapy-naive were randomized into three groups: vandetanib monotherapy, vandetanib plus gemcitabine and gemcitabine plus placebo. Median PFS was 105 days (95 % CI 72–155), 114 days (95 % CI 91–193), and 148 days (95 % CI 71–225) respectively, while mOS was 228 days (95 % CI 190–364), 284 days (95 % CI 213–359), and 307 days (95 % CI 254–523) for the three arms respectively. Thus, vandetanib alone or in association with gemcitabine did not demonstrate any superiority when compared with gemcitabine alone [51].

In conclusion, the role of VEGF inhibition in addition to chemotherapy for patients with advanced BTCs remains still investigational, but increasingly burdened by the absence of a biomarker of efficacy for VEGF inhibitors.

4-Market review

Throughout the therapeutic course of BTC patients, complications are a constant. Infections, sepsis and cholangitis often undermine patients’ health. Furthermore, chemotherapy is associated with high rate of side effects that requires spending of many economic resources.

We have considered two cost-effectiveness analysis conducted in USA and Japan. They evaluate cost-effectiveness of combination treatment with gemcitabine and cisplatin compared to treatment with gemcitabine alone. Despite being two comparable analyses in different populations, their conclusions are opposite; Roth et al. demonstrated that cisplatin and gemcitabine combination was a cost-effective alternative to gemcitabine monotherapy. Tsukiyama et al., on the contrary, suggested that gemcitabine monotherapy was a better treatment strategy for advanced BTC. These different conclusions may be due to varying health care conditions and different long-term palliative care cost between the countries.

Surprisingly, in both studies the majority of the resources were employed for supportive and palliative care rather than for drugs [56, 57].

For these reasons, systemic treatments are required not only to prolong survival, but also to limit palliative interventions. Recently, immunotherapy and target therapies have demonstrated to increase QoL and to be associated to lower rates of side effects in several cancer types as compared to chemotherapy [58-60]. For these reasons, alternative treatment strategies are also strongly encouraged in BTC patients.
5-Current research goals

Carcinogenesis is a multistep process encountering imbalance between proliferative and inhibitory stimuli, dysregulation of apoptotic signals and abnormal response to angiogenetic factors which are responsible for invasion and metastatization events [61]. It involves specific cell genome derangements that contribute to the selective growth advantage of cancer. Specific pathways govern cell fate through proliferation, cell survival, differentiation, epigenetic changes and maintenance of genome integrity [62].

The genomic heterogeneity of BTC is well-known. As previously discussed, it’s not only related to the diverse anatomical location of the tumor but also to etiology, the various risk factors and associated pathologies. Interestingly, mutations in TP53 responsible for genome integrity are very common in all subgroup of BTC but are more often observed in liver-fluke related CCA [63]. These differences will need to be considered when assessing outcome and in devising therapeutic strategies for CCA and GBC [2, 61, 64-67]. Advances in genome-wide technologies have made feasible the discovery of other possible targetable or actionable molecular alterations in BTC. Precision therapy for this group of tumors is subordinated to an enhanced understanding of genetic and molecular alteration for each subtype.

6-Scientific rationale and molecular pathogenesis

- 6.1 Proliferation and cell survival.

Several growth pathways are implicated in arising and progression of BTCs. Here we revise the most promising preclinical evidences that could, in the near future, have a clinical counterpart.

ErbB family, that includes four different receptors (ErbB1 or EGFR, ErbB2 or HER-2/neu, ErbB3 and ErbB4), have a main role in carcinogenesis processes and represents the most extensively mutated pathway of the GBC samples [68]. We have already introduced the role of EGFR and its clinical implications.

Human epidermal growth factor receptor 2 (HER2) amplification has been observed in BTCs patients with a prevalence in EH-CCA (about 20%), GBC (9.8%) and a rare incidence in IH-CCA. The prognostic meaning of HER2 has not yet been completely clarified but could become a relevant predictive factor [68, 69].

KRAS mutations occur in BTC and the reported incidence is 7-47%. It is usually associated with the alteration of other factors, such as EGFR, HER2 or MET [68, 70]. A recent work showed poor prognosis for KRAS mutated CCA that is more pronounced in the subgroup with transcriptional enrichment of genes that regulate proteasome activity [71].
Some studies reported BRAF mutations in a percentage between 0% and 22%. In a large cohort, BRAF V600E mutation was observed in 5.9% of GBC, 3% of IH-CCA and 0% of EH-CCA and no clear correlation with prognosis was detected [72, 73].

Recently, ARAF mutation (ARAFm), a member of the RAS family, has been reported in 11% of IH-CCA iCCA. ARAFm leads to an increased basal and inducible activity when compared to WT protein. Further studies need to investigate the oncogenic potential of this new target. [74].

ROS1 fusion proteins have been recently implicated in CCA carcinogenesis. The fused-in-glioblastoma-c-ros-oncogene 1 (FIG-ROS) was found in 14-16% of EH-CCA [75] and it mediated cancerogenesis in KRAS dependent mode with a high aggressiveness [76].

The expression level of hepatocyte growth factor (HGF) receptor (also known as c-Met) is amplified either in CCA and GBC. Miyamoto analyzed 247 patients and noted MET high expression in 11.7% of IH-CCA and 16.2% in EH-CCA. MET seems to play a central role in carcinogenesis through the protection from apoptosis and promoting angiogenesis and tumor invasion. In CCA it is associated with EGFR expression and represents a poor prognostic factor. Moreover, it could be linked to acquired resistance to EGFR or HER2 inhibitors [77, 78].

FGFR is a tyrosine kinase receptor involved in numerous cellular process including proliferation, angiogenesis and tissue repair. Disruption of this pathway has been implicated as driver event in biliary cancer formation. Fusions of FGFR gene have been reported in some cancer type; in BTC several gene fusions have been described, the most frequent being FGFR2-BICC1 fusion. This new protein seems to have a higher incidence in female and a link with hepatitis infection. It is constitutively active and leading to the activation of MAPK and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)/ mammalian target of rapamycin (mTOR) pathways. Moreover, FGFR translocation may confer a survival benefit. Indeed, in a western dataset a superior cancer specific survival was observed in patients with FGFR2 translocation compared to non translocated patients (123 months vs 37 months) [65, 74, 79].

Aberration in tumor suppressive gene phosphatase and tensin homolog (PTEN) has been correlated with clinical outcome. Indeed, PTEN loss has been associated with poor outcome in all BTC, particularly in combination with either activated Protein kinase B (PKB), also known as Akt or mTOR. However, genetic alteration in AKT genes, with normal level of PTEN, were associated with cancerogenesis but also with favorable prognosis. These findings suggest isolated AKT alteration could have an important role in the initiation of IH-CCA but not in progression of this subgroup [80-82].

Different pathways have been implicated in carcinogenesis and proliferative advantage in CCA. However, these pathways overlap in several points, providing a molecular reason for resistance to target therapies.
Besides, not every cancer has a proliferative signature. Sia et al., using an integrative molecular analysis technique, have identified gene signatures in IH-CCA and have correlated them with pathological features and clinical patients’ outcome. The authors describe two categories of IH-CCA: a proliferative class and an inflammatory class. The proliferative class, that accounts for 62% of cases, was typified by alterations in several oncogenes included in RAS-RAF-MEK-ERK or PIK3CA-AKT-mTOR signaling pathway, implicated in cell proliferation and cell survival, respectively.

The inflammatory class showed activation of inflammatory pathways, overexpression of cytokines (i.e. IL-6) and signal transducer and activator of transcription 3 (STAT3). STAT3 is a mediator that modulates cell growth and survival while IL-6 is an inflammatory cytokine produces either by CCAs and cholangiocytes stimulated by an inflammatory noxa. IL-6 is involved in cell survival through upregulation of Mcl-1 via AKT-dependent mechanism. Mcl-1 mediates tumor necrosis factor-related apoptosis inducing ligand (TRAIL) resistance and cell survival. IL-6 is also implicated in upregulation of Mcl-1 through a STAT3 dependent mechanism [83, 84].

- **6.2 Cell differentiation**

The Notch signaling pathway has a main role in cell differentiation, inflammation and carcinogenesis. Notch activation was implicated in de-differentiation of adult hepatocytes into precursors of IH-CCA. These studies not only show the high plasticity of liver cell but also change the traditional model according to which CCA cells derived from cholangiocytes or hepatic common progenitor cells [85]. These observations could be combined to Sia et al. data. In this work, the authors describe how gene signatures, especially the proliferation class one’s, overlap with those identified in HCC. These data provides us a second model of CCA carcinogenesis; not only based on alteration of epithelial cells of biliary tree but also on de-differentiation of adult hepatocytes. [84].

- **6.3 Epigenetic changes.**

Tumor cells may also acquire an advantage in survival and proliferation through epigenetic changes that lead to silencing of onco-suppressor genes. Mutations of isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are among the most common genetic alteration in IH-CCA (14-36%) [70, 86], with unclear prognostic significance [87]. No mutations in these genes were observed in EH-CCA and GBC. Mutant IDH proteins lead to an abnormal enzymatic activity inducing to production of 2-hydroxyglutarate (2-HG) from α-ketoglutarate (αKG), which is considered an oncometabolite and causes epigenetic changes. Furthermore, deficiency in αKG inhibits activity of αKG-dependent dioxygenase and results in altered cell differentiation, survival and extracellular matrix maturation [88, 89]. Mutant IDH blocks liver progenitor cells that, as a result of altered hepatocyte response to hepatic injury, could lead to the development of malignant lesions. Indeed, a recent work has shown that mutant IDH blocks hepatocyte differentiation through the production of 2-HG and the suppression of HNF-4α,
the main regulator of hepatocytes identity and quiescence [90]. Farshidfar et al. have associated mutant IDH with a specific gene signature characterized by high mitochondrial and low chromatin modifier gene expression. Speculating about the significance of this signature is complex for the wide number of genes and processes involved. Potentially, the combination of anti-IDH targeted therapies with anti-mitochondrial activity drugs could be exploited in the future as a therapeutic strategy [91].

- **6.4 Angiogenesis and tumor environment.**

VEGF has a central role in carcinogenesis and it has been targeted in different malignancies. In CCA, VEGF expression is reported in about 30-40% of cases and is correlated with lymph node metastasis and poor prognosis [38]. VEGF expression is reported in 50% of GBC and also in this sub-group a poor prognosis is observed [39].

BTC have a characteristic hypovascular, desmoplastic stroma that plays an important role in tumor pathogenesis and is consisting of cancer associated fibroblasts (CAF) expressing α-smooth muscle actin (α-SMA), activated macrophages and a fibrotic collagen rich extracellular matrix [92].

α-SMA positive CAFs are involved in cancer progression through production of matricellular proteins, growth factors, chemokines, and matrix metalloproteinases. Patients expressing high levels of α-SMA have poorer survival [93]. The desmoplastic matrix also allows the development of a niche fostering tumor spread rather than as a response to the anticancer treatments [94]. Transforming growth factor β (TGF-β) seems to be implicated in the generation of the niche. Indeed, preclinical models have demonstrated a reduction in fibrosis and tumor spread with TGF-β antagonist [95]. CAFs produce numerous factors involved in autocrine and paracrine signalling that promote oncogenic processes like periostin, tenascin-c, thrombospandin 1, stromal cell derived factor 1 (SDF-1), HGF and Wnt inducible signalling protein-1v (WISP1) [93]. These interact with cell signalling pathways. For example, periostin interacts with tenascin-C, HGF and SDF-1, which bind to their respective receptors, integrin, MET and CXCR4 on CCA cells, leading to activation of the PIK3CA/AKT signalling pathway.

Finally, desmoplastic stroma may be influenced also by sonic Hedgehog (Hh) signalling pathway. Preclinical models have disclosed the interplay between Hh and CAF through platelet-derivated growth factor BB [96].

Cancer associated macrophages (CaM) are implicated in formation and maintaining of the stromal microenvironment and appear to have prognostic significance. A high number of CD163+ macrophages in the stroma of resected IH-CCA correlates with poor disease-free survival [97].
Desmoplastic stroma formation is also associated with increased level of IL-6 that promotes tumor growth via autocrine and paracrine mechanisms [93].

For all these reasons, targeting stromal factors involved in cholangiocarcinogenesis or improving drug delivery through the desmoplastic stroma are attractive targets for novel therapeutics.

- **6.5 Immune system.**

  In BTC, a number of clinical and epidemiological factors might predict the efficacy of immunotherapies. Several chronic infections, such as viral hepatitis and bacterial cholangitis, are established risk factors for cholangiocarcinoma. Notably, immunotherapies have shown promising efficacy in cancer associated with infections, probably thanks to the presentation of non-self or neoantigens related with infections [98]. Furthermore, in a patient subgroup of BTC with poor prognosis has been revealed had a high mutational load, resulting in abundant tumor-specific neoantigens, and enrichment for expression of immune-related genes, including genes encoding inhibitory immune-checkpoint proteins [65]. In these patients, immune-checkpoint inhibition could permit to overcome cancer related mechanism of immune-silencing.

  A central role in immune response is played by CaM that, through the production of soluble factor such as interleukins or cytokines, modulates anticancer immune response and maintain stromal environment [97].

  In some small studies, programmed death-ligand 1 (PD-L1) expression has been evaluated on cancer specimens and on immune cells within the tumor microenvironment [99, 100]. PD-L1 is one of the most studied biomarker and levels of tumor PD-L1 expression have been associated with sensitivity to immune checkpoint inhibitor monotherapy in several tumor and they could predict response to the immunotherapies.

7- **Competitive environment and potential development issues**

- **7.1 HER2**

  HER2 also belongs to the ErbB family of tyrosine kinases receptor and it is seems to be overexpressed in approximately 10% of GBC and 26.3% EH-CCA [25]. Given the efficacy of agents targeting HER2 in other cancers types, they were tested in BTC patients, nevertheless none improved outcomes so far.

  **Lapatinib** is a dual tyrosine kinase EGFR and HER2 inhibitor; it was tested in two phase II studies in patients with advanced BTC. The first one was conducted on hepatobiliary cancer patients including 19 BTC, reaching poor results (mPFS was 1.8 months and mOS was 5.2 months) and no objective responses [101]. Later, similar results have emerged from a phase II trial involving only BTC patients: the response was extremely poor (0%),
leading to premature discontinuation of the trial [102]. The role of Trastuzumab, a mAb that targets the HER2 receptor, is so far not well defined in treatment of BTC. The only data available comes from a retrospective analysis in which Javle et al. studied BTC patients with HER2 genetic alterations or protein overexpression treated with HER2-directed therapy in combination with concurrent therapy of physician’s choice. Among the eight GBC patients who received trastuzumab, one patient experienced complete response (CR), four patients a partial response (PR), and three had stable disease (SD). The median duration of response in these patients was 40 weeks. In contrast, among five CCA patients no response was observed and disease progression occurred during treatment with trastuzumab [103]. Likewise, in 2012 Law reported a case of a patient affected by HER2 positive GBC, showing a dramatic response after nine weeks of treatment with trastuzumab and paclitaxel [104].

Neratinib, a more recent tyrosine kinase inhibitor HER2-directed is actually under evaluation in SUMMIT, an ongoing basket trial involving a variety of tumor types harboring HER2 mutations, including BTC (NCT01953926). Preliminary data, recently presented during the American Association for Cancer Research's Annual Meeting 2017 showed an ORR of 22% in BTC (9 patients) [105].

Similarly, in a phase II trial evaluating the efficacy of Afatinib - a potent, orally bioavailable ErbB Family Blocker – was tested in different malignancies including 5 BTCs presenting HER2 amplification [106]. As shown in table 1, afatinib is currently under evaluation, in association with capecitabine, in a phase I/Ib trial addressed to patients with advanced refractory solid tumors, comprising pancreatic cancer and BTCs (NCT02451553) (Table 1, New therapies under evaluation in biliary tract cancers).

Given these contradictory outcomes, HER2-directed therapy remains an open chance of treatment for BTC patients with gene amplification, especially in GBC. A phase II trial of trastuzumab-emtansine is currently ongoing in HER2-positive BTC patients (NCT02999672) (Table 1.)

- **7.2 PIK3CA/PTEN/AKT/mTOR pathway**

The PIK3CA/PTEN/AKT/mTOR pathway has drawn attention in last years as a target for new drugs development. About 12.5% of GBC patients have activating mutations of PIK3CA [107].

In a phase II Italian study, 39 patients with advanced and pre-treated BTC received everolimus - an mTOR inhibitor; mPFS was 3.2 months, and mOS was 7.7 months [108]. Since only patients who had received no more than one previous systemic chemotherapy regimen were enrolled, these results are at least in line with conventional 2nd-line chemotherapy results in advanced BTC, reporting a mPFS and mOS of 2.8 and 7.5 months respectively.
At the same time, in the Australian phase II study, everolimus was investigated in the first line setting in advanced BTC. Final results are not yet available, but preliminary findings are encouraging: ORR of 12% and mPFS of 6.0 months [109].

More extensive studies are needed to clarify the efficacy of mTOR inhibitors in the treatment of BTC.

As shown in table 1, a phase II trial using a PIK3CA inhibitor, copanlisib in CCA, in first line setting in combination with cisplatin and gemcitabine is ongoing (NCT02631590).

- **7.3 BRAF**
  
  BRAF mutations occur in a small portion of BTC patients; the most common mutation is V600E, whose frequency range from 5 to 8% [110].
  
  In the study of Hyman the efficacy of vemurafenib was evaluated in non-melanoma cancers. In the cohort of 8 CCA patients harboring BRAF V600E mutation, it was described one PR, which have persisted for more than 12 months, four SD and three progression disease (PD) [111].
  
  Furthermore, given the impressive activity noted in metastatic melanoma with BRAF V600 mutations using a combination of dabrafenib (BRAF inhibitor) and trametinib (MEK1 and MEK2 inhibitor), dual blockade merits evaluation also in this subset. A case report of a notable response in a IH-CCA patient who received this combination supports this hypothesis [112].

- **7.4 ROS, ALK, NTRK**
  
  The presence of NTRK fusions in patients diagnosed with IH-CCA have been stated around 3.5% [113]. Sporadic fusions of ROS1 (up to 8.7%) and ALK (2.6%) are also described [114].

  Compounds targeting an NTRK1/2/3, ROS1, or ALK gene rearrangement have demonstrated impressive ORR (57-86%) in a selected population of solid tumors [115].

  Based on this data and the well-known clinical activity of ALK inhibitors in non-small cell lung cancer (NSCLC) with ALK or ROS1 translocation, a phase II trial is ongoing. This trial evaluates the efficacy and safety of ceritinib in patients with IH-CCA over-expressing ROS1 or ALK (NCT02374489). The recently identified FIG-ROS fusion suggests that crizotinib therapy merits evaluation: NCT02034981 is a phase II trial of crizotinib in patients harbouring an ALK, MET, or ROS1 alteration (Table 1).

  During the most recent ASCO annual meeting, the presentation of preliminary data on larotrectinib showed a consistent and durable antitumor activity of this drug in NTRK fusion cancers, across a wide range of tumor types. Among 55 NTRK fusion patients enrolled, 2 were CCA. The ORR for the 46 patients evaluated was 78%, with responses in 12 tumor types; no data on CCA were presented [116].
7.5 FGFR

FGFR pathway is involved in cellular migration, proliferation, survival, and differentiation. FGFR mutations and fusions predominate in IH-CCA in about 16% of cases [110]. In particular, genome-wide structural analyses showed numerous translocation events concerning the FGFR2 locus, ranging between 11 and 45% in IH-CCA patients [117]. The discovery of recurrent FGFR aberrations has opened a promising therapeutic avenue.

BGJ 398, an oral FGFR inhibitor, is under evaluation in a phase II trial in advanced CCA with FGFR gene fusion/translocation after first-line chemotherapy (NCT02150967). The recent interim report of this trial was the following: 50 patients with BTC having FGFR genetic alterations were enrolled, the majority with IH-CCA. The ORR was 22% (all 8 patients with a partial response had an FGFR2 fusion) and the disease control rate (DCR) was 95% with PFS of 6 months [103].

A number of other clinical trials involving selective FGFR small molecule inhibitors - including INCB54828 (NCT02924376), BAY1163877 (NCT01976741), and the irreversible FGFR inhibitor TAS-120 (NCT02052778) - are currently in progress in early-phase trials in patients with advanced solid tumors, including BTC (Table 1).

Moreover, nonselective multi-TKIs targeting also FGFR, including ponatinib and pazopanib, have showed some activity in patients with highly pretreated IH-CCA [117].

Finally, a nonselective TKI, ARQ 087 (NCT01752920), which inhibits RET, PDGF receptor, KIT, SRC, and FGFR1–3, is currently under evaluation in a phase II trial of patients with FGFR-aberrant tumors, including FGFR2 fusion–positive advanced IH-CCA. Preliminary data from the phase I/II basket trial show that 3 of the 12 IH-CCA patients with FGFR2 fusion had a PR (DCR of 75%).

In conclusion, the preliminary data for FGFR inhibitors in advanced IH-CCA are encouraging.

7.6 IDH1-2

IDH 1 and 2 mutations are frequent in IH-CCA (9 of 40, 23%), while lacking in EH-CCA and GBC patients. Additionally, results from several researches have shown that IDH1 mutation is more common than mutation of IDH2.

Recently the findings of a dose escalation study of AG-120, an IDH1 inhibitor, in patients with advanced solid tumors having these mutations was presented by Burris et al. Of the 20 IH-CCA patients enrolled, 1 patient (5%) reached a PR and 11 patients (55%) had SD, with disease stability beyond 6 months [118].
As shown in table 1, the potential efficacy of IDH1 and IDH2 inhibitors is currently being evaluated in clinical trials involving solid tumors such as BTC that harbor these mutations (NCT02481154, NCT02073994, NCT02381886).

- **7.7 Immunotherapy**

Mechanisms involved in DNA repair are indispensable for the maintenance of genomic stability. Acquired or genetic mutations leading to defective DNA mismatch repair (MMR) are common in several tumors such as colorectal, gastric and endometrial cancer [110].

In the study of Jaivle et al regarding mutational profiling of BTC, mutations in genes involved in DNA repair - MSH6, BRCA1, BRCA2, ATM, MLH1 or MSH2 - was highly represented: 13% in IH-CCA, 26% in EH-CCA and 6% of GBC cases [103].

Available data comes from KEYNOTE-028, an ongoing, phase 1b trial of pembrolizumab monotherapy for advanced solid tumors PD-L1-positive. Patients with PD-L1-positive BTC were included, with the exception of cancer of the ampulla of Vater. Of 89 BTC patients screened for PD-L1 expression, 42% were PD-L1-positive tumors. 24 pretreated patients - including 38% who received ≥3 prior therapies - were enrolled, showing an ORR (confirmed and unconfirmed) of 17%, with 4 PR, 4 SD, and 12 PD [119].

Given the demonstrated sensibility to programmed cell death protein 1 (PD-1) blockade with checkpoint inhibitor agents (e.g pembrolizumab or nivolumab), BTC patients presenting these mutations can represent a subset where immunotherapy may be effective. A number of immunotherapy studies are currently recruiting (Table 1).

**8-Conclusion**

Treatment for advanced BTC is challenging; although cisplatin and gemcitabine are considered the standard 1st line on the basis of a consolidated phase III study, survival outcomes remain dismal; TCR is achieved in approximately 80% of cases, but mOS is generally less than one year. Second-line treatment should be offered to patients who maintain a good PS, but no schedule should be preferred above the others. To date, there is no strong evidence to support the use of combination instead of single-agent therapy neither. Data from retrospective series show that 2nd line treatment yields mPFS of 3 months and mOS of 7 months approximately. Moreover, treatment of BTC patients is encumbered with a high rate of complications, such as infections, need of biliary stenting, gastrointestinal toxicity, that have a high burden not only on patient’s care but also on social
and economical aspects. It goes without saying that every patient should be carefully evaluated for potential risks and benefit of active therapy and that every treatment, in addition to efficacy, should provide a manageable safety profile.

In the past years, despite initial encouraging reports, targeted agents have failed to provide significant changes in the history of BTC patients. In particular, anti-EGFR and anti-VEGF treatment used in addition to cisplatin and gemcitabine as 1st line treatment have provided no benefit in randomized control trials. Other targeted agents used, such as anti-MEK or anti-HER2, and data from some small non-randomized trials have shown little value and conflicting results. More recently, some other druggable targets are raising renewed interest in tailored medicine for BTC care.

9-Expert opinion

Despite a great effort to improve patients’ outcomes, in the past decades only few studies have provided practice-changing findings. The milestones of BTC care include the superiority of chemotherapy over BSC [12] and the identification of gemcitabine-cisplatin as standard treatment for advanced disease [10]. More recently, the role of adjuvant chemotherapy after resection of localized disease is being supported by randomized controlled trials [9]. These results have been achieved over a period of about 20 years and appear inadequate considering the progresses that have been made in other diseases, including gastrointestinal malignancies, in the same time span.

Undoubtedly, dealing with a rare disease is the main disadvantage researchers have to face when designing clinical trials; in the 90ies BTCs were often grouped with ampullary and pancreatic cancers. The bulk of literature available includes small trials that, in spite of being multicentric, generally have a small sample size of 40-100 patients. In addition, some of the first studies with targeted therapies were not supported by a strong rationale or an accurate patient selection; in some cases, researchers have tried to apply the same paradigms that showed success in other cancer types to BTC, an orphan disease with very few options.

We have already pointed out that the different entities that are commonly included in BTC, such as IH-CCA, EH-CCA e GBC, have also different clinical and molecular features. Sometimes they are used as stratification factors for randomization or to conduct subgroup analyses. In our opinion, this issue is a great limitation especially for studies with targeted agents because the different pathways activated or inhibited are strongly influenced by the molecular features of the tumor, which vary strongly among the entities. For example, in the first studies with anti-EGFR therapies, slightly better results were observed in the IH-CCA groups, but their real impact was never significant because of the small sample size or the retrospective character of the analyses.

With the advent of new, advanced technologies like next-generation sequencing the underpinnings of genomic
landscape of BTCs are being disclosed. To date, no distinct molecular mutation characterizes BTCs, but the scenario is scattered into several alterations that have a relatively low rate, especially if we consider the different anatomical locations. Among the druggable alterations, IDH1-2 mutations and FGFR translocations are those that show the most potential because of higher frequency and the investigation of different compounds in clinics.

In parallel with the progress of technologies, drug development in the past few years is substantially changing; trial design is moving from the standard approach from phase I to phase III trials and approval, to newest methods. More often we are observing proof-of-concept studies that lead to an accelerated approval by regulatory agencies, thanks to striking results on a limited number of patients in non-randomized phase I or II trials.

Moreover, revolutionary trials designs permit to handle multiple related questions with fewer patients. In basket trials the effect of one drug is tested at the same time but in a variety of tumor types that share the same single mutation. Umbrella trials indeed have many different treatment arms within one trial; people are assigned to a particular treatment arm of the trial based on their type of cancer and the specific molecular makeup of their disease.

Nivolumab and pembrolizumab have recently been granted FDA approval for microsatellite instability-high (MSI-H) tumors; this is the first time a cancer treatment to be approved based on a common biomarker rather than tumor type. A percentage of BTCs patients are potentially involved by this progress: similarly, some ongoing basket trials that we have introduced in the previous paragraphs, such as those directed against ROS, ALK, NTRK1/2/3 are deemed to provide interesting results for patients harboring low-frequency mutations.

Thanks to these new approaches and to the better knowledge of potentially actionable genomic alterations in BTCs it will be possible to offer a chance for tailored medicine to BTCs patients ant to meet an unmet clinical need.

Financial and competing interests disclosure: The authors report no conflicts of interest

10-References


URL: http://mc.manuscriptcentral.com/eomd Cara.Rodrigues@tandf.co.uk


54. Lowery MA, O'Reilly EM, Harding JJ et al. A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC). J Clin Oncol 2015; 33.


82. Lee D, Do IG, Choi K et al. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol 2012; 25: 131-139.


References of interest


This phase III trial provides the gold standard for 1st line treatment in BTC


This review summarizes the evolution of systemic treatments from chemotherapy to the first studies with targeted therapies


In this study a whole-genome sequencing reveals recurrent mutations and interest insights according to the etiology


This work refers to the integrated analysis of somatic mutations, RNA expression, copy number, and DNA methylation by The Cancer Genome Atlas of a set of predominantly intrahepatic CCA
Table 1 New therapies under evaluation in biliary tract cancers

<table>
<thead>
<tr>
<th>Therapeutic regimen</th>
<th>Target</th>
<th>Phase</th>
<th>ClinicalTrials.gov identifier</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VEGF and multitarget</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramucirumab</td>
<td>VEGFR2 2</td>
<td>2</td>
<td>NCT02520141</td>
<td>Recruiting</td>
</tr>
<tr>
<td>GEMCIS and ramucirumab or merestinib</td>
<td>VEGFR2 c-MET</td>
<td>2</td>
<td>NCT02711553</td>
<td>Active (not recruiting)</td>
</tr>
<tr>
<td>FOLFOX and cediranib</td>
<td>VEGFR</td>
<td>2</td>
<td>NCT01229111</td>
<td>Not recruiting (results expected)</td>
</tr>
<tr>
<td>Regorafenib</td>
<td>VEGFR1-3, c-KIT, TIE-2, PDGFR-β, C-Raf, B-Raf, p38 MAPK, FGFR1-2, Ret 2</td>
<td>2</td>
<td>NCT02115542</td>
<td>Active (not recruiting)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NCT02053376</td>
<td>Active (not recruiting)</td>
</tr>
<tr>
<td>Apatinib</td>
<td>VEGFR-2</td>
<td>2</td>
<td>NCT03144856</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Lenvatinib</td>
<td>VEGFR-2, VGFR-3</td>
<td>2</td>
<td>NCT02579616</td>
<td>Active (not recruiting)</td>
</tr>
<tr>
<td>Varlitinib + GEMCIS</td>
<td>EGFR</td>
<td>2</td>
<td>NCT02992340</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>MAPK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trametinib versus CAP/SFU</td>
<td>MEK 1/2</td>
<td>2</td>
<td>NCT02042443</td>
<td>Not recruiting (results expected)</td>
</tr>
<tr>
<td>Binimetinib (MEK162) and GEMCIS</td>
<td>MEK 1/2</td>
<td>2</td>
<td>NCT01828034</td>
<td>Active (not recruiting)</td>
</tr>
<tr>
<td>Selumetinib (at different doses) and GEMCIS</td>
<td>MEK 1/2</td>
<td>2</td>
<td>NCT02151084</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>HER 2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Afatinib</td>
<td>HER2</td>
<td>1/1b</td>
<td>NCT02451553</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Trastuzumab Emtansine</td>
<td>HER2</td>
<td>2</td>
<td>NCT02999672</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Neratinib</td>
<td>HER2</td>
<td>2</td>
<td>NCT01953926</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copanlisib + GEMCIS</td>
<td>PIK3CA</td>
<td>2</td>
<td>NCT02631590</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Entrectinib</td>
<td>NTRK1/2/3, ROS1, ALK</td>
<td>2</td>
<td>NCT02568267</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Larotrectinib</td>
<td>NTRK1/2/3</td>
<td>2</td>
<td>NCT02576431</td>
<td>Recruiting</td>
</tr>
<tr>
<td>LDK378</td>
<td>ALK, ROS1</td>
<td>2</td>
<td>NCT02374489</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Crizotinib</td>
<td>ALK, MET, ROS1</td>
<td>2</td>
<td>NCT02034981</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Immunotherapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>PD1</td>
<td>2</td>
<td>NCT03260712</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Treatment</td>
<td>Target(s)</td>
<td>Phase</td>
<td>NCT Number</td>
<td>Status</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------</td>
<td>-------</td>
<td>---------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td><strong>Cisplatine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gemcitabine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nivolumab</td>
<td>PD1</td>
<td>2</td>
<td>NCT02829918</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Pembrolizumab and GM-CSF</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab and nivolumab</td>
<td>CTLA4 and PD1</td>
<td>2</td>
<td>NCT02923934</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Pembrolizumab + CAPOX</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infiratinib</td>
<td>FGFR2</td>
<td>2</td>
<td>NCT02150967</td>
<td>Recruiting</td>
</tr>
<tr>
<td>INCB054828</td>
<td>FGFR2</td>
<td>2</td>
<td>NCT02924376</td>
<td>Recruiting</td>
</tr>
<tr>
<td>BAY1163877</td>
<td>Pan-FGFR</td>
<td>1</td>
<td>NCT01976741</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>TAS-120</strong></td>
<td>FGFR</td>
<td></td>
<td>NCT02052778</td>
<td>Recruiting</td>
</tr>
<tr>
<td>ARQ 087</td>
<td>FGFR1–3, RET, PDGFR, KIT</td>
<td>1/2</td>
<td>NCT01752920</td>
<td>Not recruiting (results expected)</td>
</tr>
<tr>
<td>AG881</td>
<td>IDH1-2</td>
<td>1</td>
<td>NCT02481154</td>
<td>Active (not recruiting)</td>
</tr>
<tr>
<td>AG-120</td>
<td>IDH1</td>
<td>1</td>
<td>NCT02073994</td>
<td>Active (not recruiting)</td>
</tr>
<tr>
<td>IDH305</td>
<td>IDH1</td>
<td>1</td>
<td>NCT02381886</td>
<td>Suspended</td>
</tr>
<tr>
<td><strong>Multiagent</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple arms based on molecular profiling</td>
<td>Multiple (EGFR, HER2, mTOR, VEGF/EGFR/ PDGFR, ALK/ROS1)</td>
<td>2</td>
<td>NCT02836847</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Sulfiniib</td>
<td>VEGFR 1,2,3, FGFR 1, CSF1R</td>
<td>2</td>
<td>NCT02966821</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Regorafenib + modified GEMOX</td>
<td>VEGFR1-3, c-KIT, TIE-2, PDGFR-β, C-Raf, B-Raf, p38 MAPK, FGFR1-2, Ret 2</td>
<td>2</td>
<td>NCT02386397</td>
<td>Recruiting</td>
</tr>
</tbody>
</table>
2-HG 2-Hydroxyglutarate

5-FU 5-Fluorouracil

αKG α-Ketoglutarate

ARAFm ARAF Mutation

α-SMA α-Smooth Muscle Actin

BSC Best Supportive Care

BTC Biliary Tract Cancer

CaM Cancer Associated Macrophages

CAF Cancer Associated Fibroblasts

CCA Cholangiocarcinoma

CK Cytokeratin

c-KIT Stem Cell Growth Factor Receptor

CR Complete Response

DCCA Distal Cholangiocarcinoma

DCR Disease Control Rate

ECOG Eastern Cooperative Oncology Group

EGFR Epidermal Growth Factor Receptor

EH-CCA Extrahepatic Cholangiocarcinoma

EMT Epithelial- Mesenchymal Transition

FGFR Fibroblast Growth Factor Receptor

FIG-ROS Fused In Glioblastoma c-ROS Oncogene 1

FOLFIRI 5- Fluorouracil/Leucovorin- Irinotecan

FOLFOX 5- Fluorouracil/Leucovorin- Oxaliplatin

GBC Gallbladder Cancer
GEMOX Gemcitabine- Oxaliplatin

HCC Hepatocellular Carcinoma

HER-2 Human Epidermal Growth Factor Receptor 2

HGF Hepatocyte Growth Factor

Hh Hedgehog

IDH1 Isocitrate Dehydrogenase 1

IDH2 Isocitrate Dehydrogenase 2

IH-CCA Intrahepatic Cholangiocarcinoma

mAbs Monoclonal Antibodies

MAPK Mitogen Activated Proteine Kinases

mGEMOX Modified Gemcitabine- Oxaliplatin

MMR Mismatch Repair

mOS Median Overall Survival

mPFS Median Progression Free Survival

MSI-H Microsatellite Instability-High

mTOR Mammalian Target of Rapamycin

NSCLC Non-Small Cell Lung Cancer

ORR Overall Response Rate

OS Overall Survival

PCCA Perihilar Cholangiocarcinoma

PD Progression Disease

PD-1 Programmed Cell Death Protein 1

PDGF Platelet-Derived Growth Factor

PD-L1 Programmed Cell Death- Ligand 1
PFS Progression Free Survival

PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

PKB Protein Kinase B

PR Partial Response

PS Performance Status

PSC Primary Sclerosing Cholangitis

PTEN Phosphatase and Tensin Homolog

QoL Quality of Life

RET Rearranged During Transfection

RR Response Rates

SD Stable Disease

SDF-1 Stromal Cell Derived Factor 1

STAT3 Signal Transducer and Activator of Transcription 3

TCR Tumor Control Rate

TGF-β Transforming Growth Factor β

TKIs Tyrosine Kinase Inhibitors

TRAIL Tumor Necrosis Factor Related Apoptosis Inducing Ligand

VEGF Vascular Endothelial Growth Factor

WISP1 Wnt Inducible Signaling Protein-1v

WT Wild Type

XELIRI Capecitabine- Irinotecan

XELOX Capecitabine- Oxaliplatin
Title

Emerging molecular target antagonists for the treatment of biliary tract cancer

Abstract

Introduction: Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is cisplatin/gemcitabine combination, whereas no standard in 2nd-line has been defined. Hence, the current goal is to better understand the biology of BTCs, discovering new treatment methods and improving clinical outcomes.

Areas covered: The development of next-generation-sequencing has unveiled the picture of the molecular signatures characterizing BTCs, leading to the identification of actionable mutations in biomarker-driven clinical trials. In this review we will cover the genetic landscape of BTC, focusing on the efficacy of existing treatments. Furthermore, we will discuss emerging molecular targets and evaluate the findings of pre-clinical studies. Finally, the encouraging results of clinical trials involving targeted therapies or immunotherapy will be reviewed.

Expert opinion: FGFR fusion rearrangements and IDH1 or IDH2 mutations are the most promising targeted treatments under evaluation. In addition, innovative trial design will allow to offer a chance for tailored medicine to infrequent subgroups of BTCs patients based on their molecular features rather than their histology.

Manuscript

Background

Biliary tract cancer (BTC) is a heterogeneous group of tumors arising from the epithelial lining of the biliary tree. The classification is based according to the anatomical location; BTC includes gallbladder cancer (GBC) and cholangiocarcinoma (CCA); the latter is further divided into intrahepatic (IH-CCA), and extrahepatic (EH-CCA), which includes EH-CCA perihilar (PCCA) and distal CCA (DCCA). IH-CCAs arise above the second order bile ducts, whereas PCCAs are located between the insertion of the cystic duct and the second order bile ducts, and DCCAs are located below the insertion of the cystic duct [1, 2].
Even though GBC, intrahepatic, perihilar and distal extrahepatic CCA are grouped as BTCs, their clinical presentation, pathobiology and management are different, and they should be viewed as separate entities. Despite being considered an infrequent cancer in the Western world, with an incidence of 1-2 cases every 100,000 inhabitants, BTCs are extremely common in South America and in some areas of Asia, with up to 96 cases/100,000 [3].

Histologically, more than 95% of BTCs are adenocarcinomas, often poorly differentiated. About 10% of EH-CCA are well differentiated papillary cancers, but mucinous (5%) and squamous cancers (2%) are also described [4]. Several classifications have been proposed for IH-CCA owing to its highly heterogeneity. The two main histological subtypes are bile ductular type (mixed), arising from small intrahepatic bile ducts, and bile duct type (mucinous), arising from large intrahepatic bile ducts. These differences are also reflected in different molecular characteristics [5]. Notably, bile ductular type IH-CCAs share clinicopathological similarities with cytokeratin (CK) 19-positive hepatocellular carcinoma (HCC), and the bile duct type IH-CCAs share phenotypic traits with PCCA and pancreatic cancers [6].

Beyond the differences, BTC have common features, such as a highly desmoplastic reaction, rich tumor microenvironment, and profound genetic heterogeneity, all contributing to the development of drug resistance and almost complete absence of curative therapies for metastatic disease. The vast majority of BTC (70%) occurs sporadically. Nevertheless, several pathologic conditions have been determined as possible risk factors such as Primary Sclerosing Cholangitis (PSC), choledochal cysts, parasitic infestation, and viral hepatitis B and C. Potential risk factors with less evidence are diabetes, alcohol, smoking, obesity and specific genetic polymorphisms [7]. Therefore, although a single trigger cannot be identified, different environmental, genetic and social factors may be rather involved and justify heterogeneous geographic distribution.

Most patients with early stage disease are asymptomatic and diagnosing BTC at an early stage remains a challenge owing to its ‘silent’ clinical presentation, difficult to access anatomical location, and highly desmoplastic, paucicellular nature, which limits the sensitivity of cytological and pathological diagnostic approaches.

Surgery is the preferred treatment option for localized BTC, but only a minority of patients (approximately 35%) has early stage disease that is amenable to surgical resection with a curative intent. Survival after radical surgery generally depends on margin status (negative-R0 or positive-R1-R2 status), vascular invasion and lymph node involvement. Even after R0 resection 3-years survival rate is approximately 40-60%, and it can be lower in...
case of lymph node positivity [8].

The unfavorable prognosis of recurrent disease drove efforts to lower the rate of relapse through postoperative adjuvant therapy. So far, the great part of the available literature was made of retrospective, non-randomized studies and meta-analyses: the majority took in consideration heterogeneous populations of patients, treated with different systemic drugs with or without radiotherapy. Recently, following the presentation of the preliminary results of the BILCAP study, a standard of care for adjuvant treatment is available. In this randomized phase III trial, postoperative capecitabine was compared to surveillance: the primary endpoint of the study was formally not met, despite a difference of 15 months in the median overall survival (mOS) estimated values (51 versus 36 months, \( p = 0.097 \)). However, mOS was significantly higher in the chemotherapy arm both after sensitivity analyses and in the per protocol analysis [9].

For patients with advanced-stage or unresectable disease, the available systemic therapies are of limited effectiveness: the mOS with the current standard-of-care regimen (gemcitabine and cisplatin) is <1 year [10] and a probability to outlive 5 years is about 5% [11].

## 2. Medical need

Randomized trials have shown that systemic chemotherapy increases survival and improves quality of life (QoL) in patients with metastatic BTC as compared with best supportive care (BSC). In the study by Glimelius, 90 patients with metastatic or locally advanced pancreatic carcinoma or BTC have been randomly assigned to 5-fluorouracil (5-FU) -based chemotherapy or BSC. A clear benefit of chemotherapy on both mOS (6 vs 2.5 months in BSC group \( p < 0.01 \)) and QoL was demonstrated [12]. More recently, modified gemcitabine and oxaliplatin (mGEMOX) proved a significant improvement in mOS not only over BSC, but also over 5-FU/folinic acid in unresectable GBC (9.5, 4.6 and 4.5 months respectively)[13].

The majority of trials in the metastatic setting were performed with fluoropyrimidine or gemcitabine monotherapy or in combination with other cytotoxic agents. 5-FU as single agent yields a variable response rates (RR) from 10% to 40%. The combination of 5FU with other drugs (etoposide, interferon, cisplatin and oxaliplatin) has proved moderate efficacy, limited overall survival (OS) benefit, and a significantly greater toxicity profile. Since the late 90s, the adoption of gemcitabine as the standard of care for patients with pancreatic cancer led to interest in its use for hepatobiliary tumors. As a single agent, gemcitabine has shown RRs ranging from 0% to 30%, whereas its association with other agents has determined advantages in survival and RRs (up to 41%) [14]. In 2007 a pooled analysis of 104 trials in advanced BTC, demonstrated the superiority
of combination therapy compared to monotherapy in RR and tumor-control-rate (TCR). Subgroup analysis also
underlined that gemcitabine and platinum association had significantly higher response and TCRs compared to
fluoropyrimidine/gemcitabine monotherapy or fluoropyrimidine plus platinum regimens [15].

Suggestions from this meta-analysis were turned into a standard of care by Valle’s Phase III ABC-02 trial. Four
hundred and ten patients with locally advanced or metastatic CCA, GBC and ampullary carcinoma were
randomly assigned to receive gemcitabine alone (1000 mg/m² days 1, 8, 15 q 28) vs gemcitabine and cisplatin
(1000 mg/m² + 25 mg/m² days 1, 8 q 21) for up to 24 weeks of treatment. After a median follow-up of 8.2
months, mOS, that was the primary endpoint of the study, was statistically improved in the combination arm
(11.7 vs. 8.1 months; p < 0.001). The benefit was preserved across the subgroups according to primary tumor
site, median progression-free-survival (mPFS) was improved (8.0 months vs. 5.0 months; p < 0.001), without
significant increase in toxicity. [10]. Following the results of this trial, a definite standard regimen for a disease
that has been “orphaned” for too long, was finally provided. Equivalent results have been replicated in the
Japanese population [16]. Other combination schemes have also been evaluated as first line treatment in phase
II trials [17-19]. Among these, gemcitabine and oxaliplatin (GEMOX) is widely used in clinical practice for its
good response rate and favorable toxicity profile, although a direct comparison with the standard of care is
lacking [13, 20].

Following a meta-analysis of the English and Japanese randomized trials, single agent gemcitabine is a
recommended option only for patients with Performance Status (PS) 2 according to Eastern Cooperative
Oncology Group (ECOG) scale [21].

After the failure of the 1st line therapy, approximately half of the patients still have a good PS and satisfactory
organ function [22], but the advantages of 2nd line therapy are still unclear. In a large retrospective analysis, 196
patients who received 2nd line treatment after gemcitabine and cisplatin/oxaliplatin, were analyzed. The most
common regimens used were 5-FU/folinic acid, FOLFIRI, XELOX, 5-FU and cisplatin: globally,
the outcome was poor, the mPFS and OS being 3.2 and 6.7 months, respectively, and no chemotherapy
regimen proved superiority over the others [23]. In another Italian retrospective analysis, PS emerged as the
most important prognostic factor to select the patients that may benefit from 2nd line treatment [24].

3-Existing treatment

In the past decade we have entered the era of targeted therapies: this strategy has modified the therapeutic
approach of many cancers but the first attempts of using targeted treatments in BTCs have been so far
unsatisfactory. Here, we revise the first studies that have explored targeted therapies in BTC.
• **3.1 EGFR family pathway**

Epidermal growth factor receptor (EGFR) is mutated and overexpressed in cancer human samples. EGFR is extensively represented in BTC, being expressed in 100% of IH-CCAs, 52.6% of EH-CCAs, and 38.5% of GBCs [25]. Mutations have been found in up to 15% of BTCs [26, 27]. EGFR activation triggers the Mitogen Activated Protein Kinases (MAPK)–ERK pathway, an oncogenic signalling pathway in cancer: it donates a proliferative advantage to cancer cell, contributes to progression through epithelial-mesenchymal transition (EMT) and leads to a poor clinical outcome [28, 29]. In preclinical studies, EGFR inhibitors tested in combination with chemotherapy have shown promising activity, providing a strong preclinical rationale for anti-EGFR therapy in BTC. Different strategies targeting EGFR have been studied such as tyrosine kinase inhibitors (TKIs) or monoclonal antibodies (mAbs) alone or in association with chemotherapy.

**Erlotinib**, a selective, reversible, orally-active EGFR inhibitor, after promising results in several phase II studies, failed to confirm its superiority in OS in a large phase III study. Compared to the combination of GEMOX, the addition of erlotinib in patients with newly diagnosed metastatic BTC significantly increased RR (40% vs 21%; \( p=0.005 \)) but mPFS and OS were not increased (4.2 vs 5.8 months \( p=0.087 \) and 9.5 months in both arms, \( p=0.611 \) respectively). Subgroup analyses showed that in patients with CCA the addition of erlotinib prolonged mPFS (5.9 months vs 3.0 months; HR 0.73, 95% CI 0.53–1.00; \( p=0.049 \)) [30].

**Cetuximab** is a mAb targeting EGFR, evaluated in combination with chemotherapy in BTC in several phase II trials. In a phase II study of cetuximab in combination with GEMOX, the treatment achieved a mPFS of 8.3 months and OS of 12.7 months with high RR [31]. Following randomized trials failed to demonstrate a significant benefit of the GEMOX and cetuximab combination. In the BINGO study, cetuximab was tested in the 1st line setting in addition to GEMOX vs GEMOX alone. Despite being well tolerated, cetuximab did not significantly improve outcomes: mPFS was 6.1 months with cetuximab and 5.5 months without cetuximab, while mOS was 11.0 months with cetuximab and 12.4 months without cetuximab [32]. In a similar study in the Asiatic population, mPFS was 6.7 months with cetuximab and 4.1 months without cetuximab (\( p = 0.05 \)), while mOS was 10.6 months vs 9.8 months respectively (\( p = 0.91 \)). KRAS mutations, that are a well-known negative predictive factor of response to anti-EGFR mAbs, were identified in 36% of tumors, and did not affect the overall response rate (ORR) or mPFS [33].

**Panitumumab**, a fully human antibody against EGFR, has been tested in combination with chemotherapy in non-randomized and randomized, phase II trials. In particular, in the Vecti-BIL trial advanced BTC patients were selected upfront for KRAS mutational status. The study revealed that the addition of panitumumab to GEMOX compared to GEMOX alone did not significantly improve mPFS, (5.3 months in experimental arm vs 4.4 months...
in control arm), neither OS (10.2 months in experimental arm vs 9.9 months in control arm) in KRAS wild type (WT) BTC patients [34].

Despite the results of a recent meta-analysis suggesting a potential role of anti-EGFR therapy in prolonging PFS and RR, the current evidence does not support its use in BTC [35].

- **3.2 MEK pathway**

Targeting the RAS/RAF/MEK/ERK pathway, a major player in the cellular processes, including proliferation and apoptosis, is thought to be a winning strategy in many cancers including BTC.

The second-generation, uncompetitive inhibitor of MEK 1/2 - selumetinib - was investigated in a phase II study of 28 advanced BTC patients. Median PFS was 3.7 months and the mOS was 9.8 months, with a 12% of ORR [52]. Recently a Phase Ib trial has tested the pharmacokinetics and toxicity profile of selumetinib in combination to cisplatin and gemcitabine. Other trials are needed to demonstrate its applicability in clinical practice [53].

Another uncompetitive inhibitor of MEK 1/2, binimetinib, after encouraging results in safety and activity during phase I studies [54], is currently under evaluation in phase II studies (NCT02151084, NCT01828034).

Recently, the open-label, multicentre, single-arm trial, evaluating pazopanib - an orally available multikinase inhibitor of VEGF (vascular endothelial growth factor) receptor, PDGF (platelet-derived growth factor) receptor, c-KIT (stem-cell growth factor receptor), fibroblast growth factor receptor (FGFR) and RAF - in addition to trametinib - an orally available highly specific inhibitor of MEK 1 and MEK 2 - showed discouraging results. Despite the trend towards increased 4-month PFS, the difference did not reach statistical significance. The mOS was 6.4 months (95% CI: 4.3–10.2) and the ORR was 5% (95% CI: 0.13–24.9%) [55].

- **3.3 VEGF**

The vascular endothelial growth factor (VEGF) pathway promotes tumor growth - by angiogenesis and vascular permeability - in several tumors including BTC [36]. In CCA, VEGF expression is reported in about 30-40% of cases and is correlated with lymphnode metastasis and poor prognosis [37, 38]. VEGF expression is reported in 50% of GBC and also in this sub-group a poor prognosis is observed [39]. Based on preclinical and clinical data supporting a VEGF-targeted approach, several studies have evaluated the effectiveness and applicability of targeted therapy (bevacizumab, sorafenib, cediranib, vandetanib) in metastatic BTC, providing only limited information, principally because of their phase II design. Therefore, the role of antiangiogenic agents in the treatment of BTC is not well defined.
Bevacizumab is a recombinant humanized mAb whose efficacy has been tested in patients affected by advanced BTC. In two studies it was tested in combination with erlotinib and in sequence with gemcitabine and oxaliplatin, without favorable results [40, 41]. More recently, a small phase II study evaluated the combination of gemcitabine, capecitabine, and bevacizumab in a first-line setting, showing a mPFS and mOS similar to those observed with standard chemotherapy (8.1 months and 11.3 months, respectively) [42]. Larsen et al. recently presented the results of a phase II trial of capecitabine, irinotecan, gemcitabine, and bevacizumab as second-line setting in 50 BTC patients. Median PFS was 3.6 months and mOS was 6.4 months [43]. To date, the role of bevacizumab on BTC has been evaluated only in single-arm studies, with no randomized study performed.

Cediranib is a potent inhibitor of the VEGF receptor tyrosine kinases -also directed against PDGF receptors and c-KIT being investigated in a recent phase II study [44]. Patients were randomized to receive cisplatin and gemcitabine plus either cediranib or placebo. Cediranib did not significantly improved mPFS (7.7 months in the cediranib arm vs. 7.4 months in the placebo arm). There was a trend towards longer OS in the experimental arm compared to placebo (14.1 vs 11.9 months, respectively) [45].

For definitive conclusions, we will have to wait for the results of the ongoing phase II trial, investigating cediranib in combination with modified FOLFOX6 in advanced BTC (NCT01229111).

Sorafenib is an oral multikinase inhibitor directed against VEGF receptors and PDGF receptor-β, and blocking downstream intracellular serine/threonine kinases, like Raf-1, WT and mutant B-Raf. After the defeats in monotherapy in several studies, the more recent conducted by Luo et al [46], Sorafenib was evaluated in combination with standard chemotherapy.

First, Moehler et al. investigated Sorafenib in the first line setting, treating patients with gemcitabine with either sorafenib or placebo. In this study, longer mPFS and OS were found in the gemcitabine plus placebo arm [47]. Then, a randomized, double-blinded, multicenter phase II trial investigating a combination of gemcitabine, cisplatin with either sorafenib or placebo demonstrated no significant difference in mPFS and mOS between the two arms [48]. Finally, a small trial conducted by Lee et al. showed that the addition of sorafenib to gemcitabine and cisplatin did not improve efficacy over historical data, but there was an increase of toxicity [49].

Sunitinib is another oral small molecular-targeted drug inhibiting several intracellular and receptor protein kinases, including VEGF and PDGF receptors, c-KIT, and rearranged during transfection (RET). In the only available phase II study, the role of sunitinib was investigated as a second-line treatment in advanced BTC demonstrating only marginal efficacy; ORR was 8.9 % and mPFS was 1.7 months [50].
Vandetanib is an orally active, multikinase inhibitor targeting VEGF receptor 2, EGFR and RET kinase. In the Italian "VanGogh" study, 165 BTC patients chemotherapy-naive were randomized into three groups: vandetanib monotherapy, vandetanib plus gemcitabine and gemcitabine plus placebo. Median PFS was 105 days (95 % CI 72–155), 114 days (95 % CI 91–193), and 148 days (95 % CI 71–225) respectively, while mOS was 228 days (95 % CI 190–364), 284 days (95 % CI 213–359), and 307 days (95 % CI 254–523) for the three arms respectively. Thus, vandetanib alone or in association with gemcitabine did not demonstrate any superiority when compared with gemcitabine alone [51].

In conclusion, the role of VEGF inhibition in addition to chemotherapy for patients with advanced BTCs remains still investigational, but increasingly burdened by the absence of a biomarker of efficacy for VEGF inhibitors.

4-Market review

Throughout the therapeutic course of BTC patients, complications are a constant. Infections, sepsis and cholangitis often undermine patients' health. Furthermore, chemotherapy is associated with high rate of side effects that require spending of many economic resources.

We have considered two cost-effectiveness analysis conducted in USA and Japan. They evaluate cost-effectiveness of combination treatment with gemcitabine and cisplatin compared to treatment with gemcitabine alone. These studies get to different conclusion, probably for different conditions in each nation. Despite being two comparable analyses in different populations, their conclusions are opposite; Indeed, Roth et al. demonstrated that cisplatin and gemcitabine combination was a cost-effective alternative to gemcitabine monotherapy. However, Tsukiyama et al., on the contrary, suggested that gemcitabine monotherapy was a better treatment strategy for advanced BTC. These different conclusions may be due to varying health care conditions and probably because of different long-term palliative care cost in Japan than in the USA between the countries.

Surprisingly, in both studies the majority of the resources were employed for supportive and palliative care rather than for drugs [56, 57].

For these reasons, systemic treatments are required not only to prolong survival, but also to limit palliative interventions. Recently, immunotherapy and target therapies have demonstrated to increase QoL and to be associated to lower rates of side effects in several cancer types as compared to chemotherapy [58-60]. For these reasons, alternative treatment strategies are also strongly encouraged in BTC patients.
5. Current research goals

Carcinogenesis is a multistep process encountering imbalance between proliferative and inhibitory stimuli, dysregulation of apoptotic signals and abnormal response to angiogenetic factors which are responsible for invasion and metastatization events [61]. It involves specific cell genome derangements that contribute to the selective growth advantage of cancer. Specific pathways govern cell fate through proliferation, cell survival, differentiation, epigenetic changes and maintenance of genome integrity [62].

The genomic heterogeneity of BTC is well-known. As previously discussed, it’s not only related to the diverse anatomical location of the tumor but also to etiology, the various risk factors and associated pathologies. Interestingly, mutations in TP53 responsible for genome integrity are very common in all subgroup of BTC but are more often observed in liver-fluke related CCA [63]. These differences will need to be considered when assessing outcome and in devising therapeutic strategies for CCA and GBC [2, 61, 64-67]. Advances in genome-wide technologies have made feasible the discovery of other possible targetable or actionable molecular alterations in BTC. Precision therapy for this group of tumors is subordinated to an enhanced understanding of genetic and molecular alteration for each subtype.

6. Scientific rationale and molecular pathogenesis

6.1 Proliferation and cell survival.

Several growth pathways are implicated in arising and progression of BTCs. Here we revise the most promising preclinical evidences that could, in the near future, have a clinical counterpart.

ErbB family, that includes four different receptors (ErbB1 or EGFR, ErbB2 or HER-2/neu, ErbB3 and ErbB4), have a main role in carcinogenesis processes and represents the most extensively mutated pathway of the GBC samples [68]. We have already introduced the role of EGFR and its clinical implications.

Human epidermal growth factor receptor 2 (HER2) amplification has been observed in BTCs patients with a prevalence in EH-CCA (about 20%), GBC (9.8%) and a rare incidence in IH-CCA. The prognostic meaning of HER2 has not yet been completely clarified but could become a relevant predictive factor [68, 69].

KRAS mutations occur in BTC and the reported incidence is 7-47%. It is usually associated with the alteration of other factors, such as EGFR, HER2 or MET [68, 70]. A recent work showed poor prognosis for KRAS mutated CCA that is more pronounced in the subgroup with transcriptional enrichment of genes that regulate proteasome activity [71].
Some studies reported BRAF mutations in a percentage between 0% and 22%. In a large cohort, BRAF V600E mutation was observed in 5.9% of GBC, 3% of IH-CCA and 0% of EH-CCA and no clear correlation with prognosis was detected [72, 73].

Recently, ARAF mutation (ARAFm), a member of the RAS family, has been reported in 11% of IH-CCA iCCA. ARAFm leads to an increased basal and inducible activity when compared to WT protein. Further studies need to investigate the oncogenic potential of this new target. [74].

ROS1 fusion proteins have been recently implicated in CCA carcinogenesis. The fused-in-glioblastoma-c-ros-oncogene 1 (FIG-ROS) was found in 14-16% of EH-CCA [75] and it mediated cancerogenesis in KRAS dependent mode with a high aggressiveness [76].

The expression level of hepatocyte growth factor (HGF) receptor (also known as c-Met) is amplified in either CCA and GBC. Miyamoto analyzed 247 patients and noted MET high expression in 11.7% of IH-CCA and 16.2% in EH-CCA. MET seems to play a central role in carcinogenesis through the protection from apoptosis and promoting angiogenesis and tumor invasion. In CCA it is associated with EGFR expression and represents a poor prognostic factor. Moreover, it could be linked to acquired resistance to EGFR or HER2 inhibitors [77, 78].

FGFR is a tyrosine kinase receptor involved in numerous cellular processes including proliferation, angiogenesis and tissue repair. Disruption of this pathway has been implicated as a driver event in biliary cancer formation. Fusions of FGFR gene have been reported in some cancer types; in BTC several gene fusions have been described, the most frequent being FGFR2-BICC1 fusion. This new protein seems to have a higher incidence in female and a link with hepatitis infection. It is constitutively active and leading to the activation of MAPK and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)/ mammalian target of rapamycin (mTOR) pathways. Moreover, FGFR translocation may confer a survival benefit. Indeed, in a western dataset a superior cancer specific survival was observed in patients with FGFR2 translocation compared to non translocated patients (123 months vs 37 months) [65, 74, 79].

Aberration in tumor suppressive gene phosphatase and tensin homolog (PTEN) has been correlated with clinical outcome. Indeed, PTEN loss has been associated with poor outcome in all BTC, particularly in combination with either activated Protein kinase B (PKB), also known as Akt or mTOR. However, genetic alteration in AKT genes, with normal level of PTEN, were associated with cancerogenesis but also with favorable prognosis. These findings suggest isolated AKT alteration could have an important role in the initiation of IH-CCA but not in progression of this subgroup [80-82].

Different pathways have been implicated in carcinogenesis and proliferative advantage in CCA. However, these pathways overlap in several points, providing a molecular reason for resistance to target therapies.
Besides, not every cancer has a proliferative signature. Sia et al., using an integrative molecular analysis technique, have identified gene signatures in IH-CCA and have correlated them with pathological features and clinical patients’ outcome. The authors describe two categories of IH-CCA: a proliferative class and an inflammatory class. The proliferative class, that accounts for 62% of cases, was typified by alterations in several oncogenes included in RAS-RAF-MEK-ERK or PIK3CA-AKT-mTOR signaling pathway, implicated in cell proliferation and cell survival, respectively.

The inflammatory class showed activation of inflammatory pathways, overexpression of cytokines (i.e. IL-6) and signal transducer and activator of transcription 3 (STAT3). STAT3 is a mediator that modulates cell growth and survival while IL-6 is an inflammatory cytokine produces either by CCAs and cholangiocytes stimulated by an inflammatory noxa. IL-6 is involved in cell survival through upregulation of Mcl-1 via AKT-dependent mechanism. Mcl-1 mediates tumor necrosis factor-related apoptosis inducing ligand (TRAIL) resistance and cell survival. IL-6 is also implicated in upregulation of Mcl-1 through a STAT3 dependent mechanism [83, 84].

6.2 Cell differentiation.

The Notch signaling pathway has a main role in cell differentiation, inflammation and carcinogenesis. Notch activation was implicated in de-differentiation of adult hepatocytes into precursors of IH-CCA. These studies not only show the high plasticity of liver cell but also change the traditional model according to which CCA cells derived from cholangiocytes or hepatic common progenitor cells [85]. These observations could be combined to Sia et al. data. In this work, the authors describe how gene signatures, especially the proliferation class ones, overlap with those identified in HCC. These data provides us a second model of CCA carcinogenesis; not only based on alteration of epithelial cells of biliary tree but also on de-differentiation of adult hepatocytes.[84].

6.3 Epigenetic changes.

Tumor cells may also acquire an advantage in survival and proliferation through epigenetic changes that lead to silencing of onco-suppressor genes. Mutations of isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are among the most common genetic alteration in IH-CCA (14-36%) [70, 86], with unclear prognostic significance [87]. No mutations in these genes were observed in EH-CCA and GBC. Mutant IDH proteins lead to an abnormal enzymatic activity inducing to production of 2-hydroxyglutarate (2-HG) from α-ketoglutarate (αKG), which is considered an oncometabolite and causes epigenetic changes. Furthermore, deficiency in αKG inhibits activity of αKG-dependent dioxygenase and results in altered cell differentiation, survival and extracellular matrix maturation [88, 89]. Mutant IDH blocks liver progenitor cells that, as a result of altered hepatocyte response to hepatic injury, could lead to the development of malignant lesions. Indeed, a recent work has shown that mutant IDH blocks hepatocyte differentiation through the production of 2-HG and the suppression of HNF-4α,
the main regulator of hepatocytes identity and quiescence [90]. Farshidfar et al. have associated mutant IDH with a specific gene signature characterized by high mitochondrial and low chromatin modifier gene expression. Speculating about the significance of this signature is complex for the wide number of genes and processes involved. Potentially, the combination of anti-IDH targeted therapies with anti-mitochondrial activity drugs could be exploited in the future as a therapeutic strategy [91].

- **6.4 Angiogenesis and tumor environment.**

VEGF has a central role in carcinogenesis and it has been targeted in different malignancies. In CCA, VEGF expression is reported in about 30-40% of cases and is correlated with lymph node metastasis and poor prognosis [38]. VEGF expression is reported in 50% of GBC and also in this sub-group a poor prognosis is observed [39].

BTC have a characteristic hypovascular, desmoplastic stroma that plays an important role in tumor pathogenesis and is consisting of cancer associated fibroblasts (CAF) expressing α-smooth muscle actin (α-SMA), activated macrophages and a fibrotic collagen rich extracellular matrix [92].

α-SMA positive CAFs are involved in cancer progression through production of matricellular proteins, growth factors, chemokines, and matrix metalloproteinases. Patients expressing high levels of α-SMA have poorer survival [93]. The desmoplastic matrix also allows the development of a niche fostering tumor spread rather than as a response to the anticancer treatments [94]. Transforming growth factor β (TGF-β) seems to be implicated in the generation of the niche. Indeed, preclinical models have demonstrated a reduction in fibrosis and tumor spread with TGF-β antagonist [95].

CAFs produce numerous factors involved in autocrine and paracrine signalling that promote oncogenic processes like periostin, tenascin-c, thrombospondin 1, stromal cell derived factor 1 (SDF-1), HGF and Wnt inducible signalling protein-1v (WISP1) [93]. These interact with cell signalling pathways. For example, periostin interacts with tenascin-C, HGF and SDF-1, which bind to their respective receptors, integrin, MET and CXCR4 on CCA cells, leading to activation of the PIK3CA/AKT signalling pathway.

Finally, desmoplastic stroma may be influenced also by sonic Hedgehog (Hh) signalling pathway. Preclinical models have disclosed the interplay between Hh and CAF through platelet-derivated growth factor BB [96].

Cancer associated macrophages (CaM) are implicated in formation and maintaining of the stromal microenvironment and appear to have prognostic significance. A high number of CD163+ macrophages in the stroma of resected IH-CCA correlates with poor disease-free survival [97].
Desmoplastic stroma formation is also associated with increased level of IL-6 that promotes tumor growth via autocrine and paracrine mechanisms [93].

For all these reasons, targeting stromal factors involved in cholangiocarcinogenesis or improving drug delivery through the desmoplastic stroma are attractive targets for novel therapeutics.

6.5 Immune system.

In BTC, a number of clinical and epidemiological factors might predict the efficacy of immunotherapies coexist. Several chronic infections, such as viral hepatitis and bacterial cholangitis, are established risk factors for cholangiocarcinoma. Notably, immunotherapies have shown promising efficacy in cancer associated with infections, probably thanks to the presentation of non-self or neoantigens related with infections [98]. Furthermore, in a patient subgroup of BTC with poor prognosis has been revealed had a high mutational load, resulting in abundant tumor-specific neoantigens, and enrichment for expression of immune-related genes, including genes encoding inhibitory immune-checkpoint proteins [65]. In these patients, immune-checkpoint inhibition could permit to overcome cancer related mechanism of immune-silencing.

A central role in immune response is played by CaM that, through the production of soluble factor such as interleukins or cytokines, modulates anticancer immune response and maintain stromal environment [97].

In some small studies, programmed death-ligand 1 (PD-L1) expression has been evaluated on cancer specimens and on immune cells within the tumor microenvironment [99, 100]. PD-L1 is one of the most studied biomarker and levels of tumor PD-L1 expression have been associated with sensitivity to immune checkpoint inhibitor monotherapy in several tumor and they could predict response to the immunotherapies.

7. Competitive environment and Potential development issues

7.1 HER2

HER2 also belongs to the ErbB family of tyrosine kinases receptor and it is seems to be overexpressed in approximately 10% of GBC and 26.3% EH-CCA [25]. Given the efficacy of agents targeting HER2 in other cancers types, they were tested in BTC patients, nevertheless none improved outcomes so far. Lapatinib is a dual tyrosine kinase EGFR and HER2 inhibitor; it was tested in two phase II studies in patients with advanced BTC. The first one was conducted on hepatobiliary cancer patients including 19 BTC, reaching poor results (mPFS was 1.8 months and mOS was 5.2 months) and no objective responses [101]. Later, similar results have emerged from a phase II trial involving only BTC patients: the response was extremely poor (0%,
leading to premature discontinuation of the trial [102]. The role of Trastuzumab, a mAb that targets the HER2 receptor, is so far not well defined in treatment of BTC. The only data available comes from a retrospective analysis in which Javle et al. studied BTC patients with HER2 genetic alterations or protein overexpression treated with HER2-directed therapy in combination with concurrent therapy of physician’s choice. Among the eight GBC patients who received trastuzumab, one patient experienced complete response (CR), four patients a partial response (PR), and three had stable disease (SD). The median duration of response in these patients was 40 weeks. In contrast, among five CCA patients no response was observed and disease progression occurred during treatment with trastuzumab [103]. Likewise, in 2012 Law reported a case of a patient affected by HER2 positive GBC, showing a dramatic response after nine weeks of treatment with trastuzumab and paclitaxel [104].

Neratinib, a more recent tyrosine kinase inhibitor HER2-directed is actually under evaluation in SUMMIT, an ongoing basket trial involving a variety of tumor types harboring HER2 mutations, including BTC (NCT01953926). Preliminary data, recently presented during the American Association for Cancer Research’s Annual Meeting 2017 showed an ORR of 22% in BTC (9 patients) [105].

Similarly, in a phase II trial evaluating the efficacy of Afatinib - a potent, orally bioavailable ErbB Family Blocker – was tested in different malignancies including 5 BTCs presenting HER2 amplification [106]. As shown in table 1, afatinib is currently under evaluation, in association with capecitabine, in a phase I/IIb trial addressed to patients with advanced refractory solid tumors, comprising pancreatic cancer and BTCs (NCT02451553) (Table 1, New therapies under evaluation in biliary tract cancers).

Given these contradictory outcomes, HER2-directed therapy remains an open chance of treatment for BTC patients with gene amplification, especially in GBC. A phase II trial of trastuzumab-emptansine is currently ongoing in HER2-positive BTC patients (NCT02999672). (Table 1, New therapies under evaluation in biliary tract cancers)

- **7.2 PIK3CA/PTEN/AKT/mTOR pathway**

The PIK3CA/PTEN/AKT/mTOR pathway has drawn attention in last years as a target for new drugs development. About 12.5% of GBC patients have activating mutations of PIK3CA [107].

In a phase II Italian study, 39 patients with advanced and pre-treated BTC received everolimus - an mTOR inhibitor; mPFS was 3.2 months, and mOS was 7.7 months [108]. Since only patients who had received no more than one previous systemic chemotherapy regimen were enrolled, these results are at least in line with...
conventional 2nd-line chemotherapy results in advanced BTC, reporting a mPFS and mOS of 2.8 and 7.5 months respectively.

At the same time, in the Australian phase II study, everolimus was investigated in the first line setting in advanced BTC. Final results are not yet available, but preliminary findings are encouraging: ORR of 12% and mPFS of 6.0 months [109].

More extensive studies are needed to clarify the efficacy of mTOR inhibitors in the treatment of BTC.

As shown in Table 1, a phase II trial using a PIK3CA inhibitor, copanlisib in CCA, in first line setting in combination with cisplatin and gemcitabine is ongoing (NCT02631590) Table 1.

- **7.3 BRAF**

BRAF mutations occur in a small portion of BTC patients; the most common mutation is V600E, whose frequency range from 5 to 8% [110].

In the study of Hyman the efficacy of vemurafenib was evaluated in non-melanoma cancers. In the cohort of 8 CCA patients harboring BRAF V600E mutation, it was described one PR, which have persisted for more than 12 months, four SD and three progression disease (PD) [111].

Furthermore, given the impressive activity noted in metastatic melanoma with BRAF V600 mutations using a combination of dabrafenib (BRAF inhibitor) and trametinib (MEK1 and MEK2 inhibitor), dual blockade merits evaluation also in this subset. A case report of a notable response in a IH-CCA patient who received this combination supports this hypothesis [112].

- **7.4 ROS, ALK, NTRK**

The presence of NTRK fusions in patients diagnosed with IH-CCA have been stated around 3.5% [113]. Sporadic fusions of ROS1 (up to 8.7%) and ALK (2.6%) are also described [114].

Compounds targeting an NTRK1/2/3, ROS1, or ALK gene rearrangement have demonstrated impressive ORR (57-86%) in a selected population of solid tumors [115].

Based on this data and the well-known clinical activity of ALK inhibitors in non-small cell lung cancer (NSCLC) with ALK or ROS1 translocation, a phase II trial is ongoing. This trial evaluates the efficacy and safety of ceritinib in patients with IH-CCA over-expressing ROS1 or ALK (NCT02374489). The recently identified FIG-ROS fusion suggests that crizotinib therapy merits evaluation: NCT02034981 is a phase II trial of crizotinib in patients harbouring an ALK, MET, or ROS1 alteration [Table 1].

During the most recent ASCO annual meeting, the presentation of preliminary data on larotrectinib showed a consistent and durable antitumor activity of this drug in NTRK fusion cancers, across a wide range of tumor
types. Among 55 NTRK fusion patients enrolled, 2 were CCA. The ORR for the 46 patients evaluated was 78%, with responses in 12 tumor types; no data on CCA were presented [116].

- **7.5 FGFR**

FGFR pathway is involved in cellular migration, proliferation, survival, and differentiation. FGFR mutations and fusions predominate in IH-CCA in about 16% of cases [110]. In particular, genome-wide structural analyses showed numerous translocation events concerning the FGFR2 locus, ranging between 11 and 45% in IH-CCA patients [117]. The discovery of recurrent FGFR aberrations has opened a promising therapeutic avenue.

BGJ 398, an oral FGFR inhibitor, is under evaluation in a phase II trial in advanced CCA with FGFR gene fusion/translocation after first-line chemotherapy (NCT02150967). The recent interim report of this trial was the following: 50 patients with BTC having FGFR genetic alterations were enrolled, the majority with IH-CCA. The ORR was 22% (all 8 patients with a partial response had an FGFR2 fusion) and the disease control rate (DCR) was 95% with PFS of 6 months [103].

A number of other clinical trials involving selective FGFR small molecule inhibitors - including INC54828 (NCT02924376), BAY1163877 (NCT01976741), and the irreversible FGFR inhibitor TAS-120 (NCT02052778) - are currently in progress in early-phase trials in patients with advanced solid tumors, including BTC (Table 1).

Moreover, nonselective multi-TKIs targeting also FGFR, including ponatinib and pazopanib, have showed some activity in patients with highly pretreated IH-CCA [117].

Finally, a nonselective TKI, ARQ 087 (NCT01752920), which inhibits RET, PDGF receptor, KIT, SRC, and FGFR1–3, is currently under evaluation in a phase II trial of patients with FGFR-aberrant tumors, including FGFR2 fusion–positive advanced IH-CCA. Preliminary data from the phase I/II basket trial show that 3 of the 12 IH-CCA patients with FGFR2 fusion had a PR (DCR of 75%).

In conclusion, the preliminary data for FGFR inhibitors in advanced IH-CCA are encouraging.

- **7.6 IDH1-2**

IDH 1 and 2 mutations are frequent in IH-CCA (9 of 40, 23%), while lacking in EH-CCA and GBC patients. Additionally, results from several researches have shown that IDH1 mutation is more common than mutation of IDH2.

Recently the findings of a dose escalation study of AG-120, an IDH1 inhibitor, in patients with advanced solid tumors having these mutations was presented by Burris et al. Of the 20 IH-CCA patients enrolled, 1 patient (5%) reached a PR and 11 patients (55%) had SD, with disease stability beyond 6 months [118].
As shown in Table 1, the potential efficacy of IDH1 and IDH2 inhibitors is currently being evaluated in clinical trials involving solid tumors such as BTC that harbor these mutations (NCT02481154, NCT02073994, NCT02381886).

### 7.7 Immunotherapy

Mechanisms involved in DNA repair are indispensable for the maintenance of genomic stability. Acquired or genetic mutations leading to defective DNA mismatch repair (MMR) are common in several tumors such as colorectal, gastric and endometrial cancer [110].

In the study of Jaivle et al regarding mutational profiling of BTC, mutations in genes involved in DNA repair - MSH6, BRCA1, BRCA2, ATM, MLH1 or MSH2 - was highly represented: 13% in IH-CCA, 26% in EH-CCA and 6% of GBC cases [103].

Available data comes from KEYNOTE-028, an ongoing, phase 1b trial of pembrolizumab monotherapy for advanced solid tumors PD-L1-positive. Patients with PD-L1-positive BTC were included, with the exception of cancer of the ampulla of Vater. Of 89 BTC patients screened for PD-L1 expression, 42% were PD-L1-positive tumors. 24 pretreated patients - including 38% who received ≥3 prior therapies - were enrolled, showing an ORR (confirmed and unconfirmed) of 17%, with 4 PR, 4 SD, and 12 PD [119].

Given the demonstrated sensibility to programmed cell death protein 1 (PD-1) blockade with checkpoint inhibitor agents (e.g pembrolizumab or nivolumab), BTC patients presenting these mutations can represent a subset where immunotherapy may be effective. A number of immunotherapy studies are currently recruiting [Table 1].

### 8. Conclusion

Treatment for advanced BTC is challenging; although cisplatin and gemcitabine are considered the standard 1st line on the basis of a consolidated phase III study, survival outcomes remain dismal; TCR is achieved in approximately 80% of cases, but mOS is generally less than one year. Second-line treatment should be offered to patients who maintain a good PS, but no schedule should be preferred above the others. To date, there is no strong evidence to support the use of combination instead of single-agent therapy neither. Data from retrospective series show that 2nd line treatment yields mPFS of 3 months and mOS of 7 months approximately. Moreover, treatment of BTC patients is encumbered with a high rate of complications, such as infections, need of biliary stenting, gastrointestinal toxicity, that have a high burden not only on patient’s care but also on social
and economical aspects. It goes without saying that every patient should be carefully evaluated for potential risks and benefit of active therapy and that every treatment, in addition to efficacy, should provide a manageable safety profile.

In the past years, despite initial encouraging reports, targeted agents have failed to provide significant changes in the history of BTC patients. In particular, anti-EGFR and anti-VEGF treatment used in addition to cisplatin and gemcitabine as 1st line treatment have provided no benefit in randomized control trials. Other targeted agents used, such as anti-MEK or anti-HER2, and data from some small non-randomized trials have shown little value and conflicting results. More recently, some other druggable targets are raising renewed interest in tailored medicine for BTC care.

**9 Expert opinion**

Despite a great effort to improve patients’ outcomes, in the past decades only few studies have provided practice-changing findings. The milestones of BTC care include the superiority of chemotherapy over BSC [12] and the identification of gemcitabine-cisplatin as standard treatment for advanced disease [10]. More recently, the role of adjuvant chemotherapy after resection of localized disease is being supported by randomized controlled trials [9]. These results have been achieved over a period of about 20 years and appear inadequate considering the progresses that have been made in other diseases, including gastrointestinal malignancies, in the same time span.

Undoubtedly, dealing with a rare disease is the main disadvantage researchers have to face when designing clinical trials; in the 90ies BTCs were often grouped with ampullary and pancreatic cancers. The bulk of literature available includes small trials that, in spite of being multicentric, generally have a small sample size of 40-100 patients. In addition, some of the first studies with targeted therapies were not supported by a strong rationale or an accurate patient selection; in some cases, researchers have tried to apply the same paradigms that showed success in other cancer types to BTC, an orphan disease with very few options.

We have already pointed out that the different entities that are commonly included in BTC, such as IH-CCA, EH-CCA e GBC, have also different clinical and molecular features. Sometimes they are used as stratification factors for randomization or to conduct subgroup analyses. In our opinion, this issue is a great limitation especially for studies with targeted agents because the different pathways activated or inhibited are strongly influenced by the molecular features of the tumor, which vary strongly among the entities. For example, in the first studies with anti-EGFR therapies, slightly better results were observed in the IH-CCA groups, but their real impact was never significant because of the small sample size or the retrospective character of the analyses.

With the advent of new, advanced technologies like next-generation sequencing the underpinnings of genomic
landscape of BTCs are being disclosed. To date, no distinct molecular mutation characterizes BTCs, but the scenario is scattered into several alterations that have a relatively low rate, especially if we consider the different anatomical locations. Among the druggable alterations, IDH1-2 mutations and FGFR translocations are those that show the most potential because of higher frequency and the investigation of different compounds in clinics.

In parallel with the progress of technologies, drug development in the past few years is substantially changing; trial design is moving from the standard approach from phase I to phase III trials and approval, to newest methods. More often we are observing proof-of-concept studies that lead to an accelerated approval by regulatory agencies, thanks to striking results on a limited number of patients in non-randomized phase I or II trials.

Moreover, revolutionary trials designs permit to handle multiple related questions with fewer patients. In basket trials the effect of one drug is tested at the same time but in a variety of tumor types that share the same single mutation. Umbrella trials indeed have many different treatment arms within one trial; people are assigned to a particular treatment arm of the trial based on their type of cancer and the specific molecular makeup of their disease.

Nivolumab and pembrolizumab have recently been granted FDA approval for microsatellite instability-high (MSI-H) tumors; this is the first time a cancer treatment to be approved based on a common biomarker rather than tumor type. A percentage of BTCs patients are potentially involved by this progress: similarly, some ongoing basket trials that we have introduced in the previous paragraphs, such as those directed against ROS, ALK, NTRK1/2/3 are deemed to provide interesting results for patients harboring low-frequency mutations.

Thanks to these new approaches and to the better knowledge of potentially actionable genomic alterations in BTCs it will be possible to offer a chance for tailored medicine to BTCs patients ant to and to meet an unmet clinical need.

**Financial and competing interests disclosure:** The authors report no conflicts of interest

**References**


54. Lowery MA, O'Reilly EM, Harding JJ et al. A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC). J Clin Oncol 2015; 33.


82. Lee D, Do IG, Choi K et al. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol 2012; 25: 131-139.


References of interest


This phase III trial provides the gold standard for 1st line treatment in BTC


This review summarizes the evolution of systemic treatments from chemotherapy to the first studies with targeted therapies


In this study a whole-genome sequencing reveals recurrent mutations and interest insights according to the etiology


This work refers to the integrated analysis of somatic mutations, RNA expression, copy number, and DNA methylation by The Cancer Genome Atlas of a set of predominantly intrahepatic CCA